Solution - 1 ml:
- Active substance: phenylephrine hydrochloride 10 mg;
- Excipients: glycerin; water for injections
Solution for injection, in ampoules of 1 ml, 10 pieces in cardboard packs.
Description of the dosage form
Transparent colorless liquid.
pharmachologic effect
Vasoconstrictor, alpha-adrenomimetic.
Pharmacokinetics
Metabolized in the liver and gastrointestinal tract (without the participation of catechol-O-methyltransferase). Excreted by the kidneys in the form of metabolites.
Pharmacodynamics
Alpha1-adrenergic stimulant, which has little effect on beta-adrenergic receptors of the heart. It is not a catecholamine (contains only one hydroxyl group in the aromatic ring). Causes constriction of arterioles and increased blood pressure (with possible reflex bradycardia). Compared to norepinephrine and epinephrine, it increases blood pressure less sharply, but acts longer (less susceptible to the action of catechol-O-methyltransferase). Does not cause an increase in minute blood volume.
The action begins immediately after administration and continues for 5-20 minutes (after intravenous administration), 50 minutes (with subcutaneous administration), 1-2 hours (after intramuscular administration).
Indications for use Mezaton
- Arterial hypotension;
- Shock conditions (including traumatic, toxic shock);
- Vascular insufficiency(including against the background of an overdose of vasodilators);
- Vasomotor and allergic rhinitis;
Contraindications to the use of Mezaton
- Increased sensitivity to the drug;
- hypertrophic obstructive cardiomyopathy;
- pheochromocytoma;
- ventricular fibrillation.
Mezaton Use during pregnancy and children
Contraindicated.
Mezaton Side effects
From the cardiovascular system: increased blood pressure, palpitations, ventricular fibrillation, arrhythmia, bradycardia, cardialgia.
From the side of the central nervous system: dizziness, fear, insomnia, anxiety, weakness, headache, tremor, paresthesia, convulsions, cerebral hemorrhage.
Other: pallor of the facial skin, ischemia of the skin at the injection site, in isolated cases, necrosis and scab formation are possible when it enters the tissue or during subcutaneous injections, allergic reactions.
Drug interactions
Diuretics and antihypertensive drugs. Mezaton reduces the antihypertensive effect of diuretics and antihypertensive drugs (methyldopa, mecamylamine, guanadrel, guanethidine).
Phenothiazines, alpha-blockers (phentolamine) reduce the hypertensive effect.
MAO inhibitors (furazolidone, procarbazine, selegiline), oxytocin, ergot alkaloids, tricyclic antidepressants, methylphenidate, adrenergic stimulants enhance the pressor effect and arrhythmogenicity of phenylephrine.
Beta-blockers reduce cardiac stimulatory activity; in the presence of reserpine, arterial hypertension is possible (as a result of depletion of catecholamine reserves in adrenergic endings, sensitivity to adrenergic agonists increases).
Inhalation anesthetics (chloroform, enflurane, halothane, isoflurane, methoxyflurane) increase the risk of severe atrial and ventricular arrhythmias because they sharply increase the sensitivity of the myocardium to sympathomimetics.
Ergometrine, ergotamine, methylergometrine, oxytocin, doxapram increase the severity of the vasoconstrictor effect.
Nitrates. Mezaton reduces the antianginal effect of nitrates, which, in turn, can reduce the pressor effect of sympathomimetics and the risk of arterial hypotension (simultaneous use is possible depending on the achievement of the required therapeutic effect).
Thyroid hormones increase (mutually) the effect and the associated risk of coronary insufficiency (especially with coronary atherosclerosis).
Mezaton dosage
Intravenously, in a stream, slowly.
For collapse - 0.1-0.3-0.5 ml of a 1% solution, diluted in 20 ml of a 5% dextrose solution or 0.9% sodium chloride solution. If necessary, the administration is repeated.
Intravenous, drip - 1 ml of 1% solution in 250-500 ml of 5% dextrose solution.
Subcutaneously or intramuscularly.
Adults - 0.3-1 ml of 1% solution 2-3 times a day; children over 15 years of age with arterial hypotension during spinal anesthesia- 0.5-1 mg/kg.
To constrict the blood vessels of the mucous membranes and reduce inflammatory phenomena lubricate or instill (solution concentrations - 0.125, 0.25, 0.5, 1%).
At local anesthesia add 0.3-0.5 ml of 1% solution per 10 ml of anesthetic solution.
Maximum doses for adults. Subcutaneously and intramuscularly: single - 10 mg, daily - 50 mg; intravenously: single - 5 mg, daily - 25 mg.
Overdose
Ventricular extrasystole, short paroxysms ventricular tachycardia, a feeling of heaviness in the head and limbs, a significant increase in blood pressure.
Precautionary measures
During treatment you should monitor ECG indicators, blood pressure, minute volume of blood, blood circulation in the extremities and injection site. In patients with arterial hypertension in case of drug-induced collapse, it is enough to maintain SBP at a level lower than usual by 30-40 mmHg. Before or during therapy shock states correction of hypovolemia, hypoxia, acidosis and hypercapnia is mandatory.
Sharp increase Blood pressure, severe bradycardia or tachycardia, persistent cardiac arrhythmias require discontinuation of treatment.
To prevent a recurrent decrease in blood pressure after discontinuation of the drug, the dose should be reduced gradually, especially after long infusion. The infusion is resumed if the SBP decreases to 70-80 mmHg. Art.
It should be borne in mind that the use of vasoconstrictors during labor to correct arterial hypotension or as additives to local anesthetics against the backdrop of stimulants labor(vasopressin, ergotamine, ergometrine, methylergometrine) may lead to a persistent increase in blood pressure in the postpartum period.
With age, the number of adrenergic receptors sensitive to phenylephrine decreases. MAO inhibitors, increasing the pressor effect of sympathomimetics, can cause headaches, arrhythmias, vomiting, hypertensive crisis Therefore, when patients are taking MAO inhibitors in the previous 2-3 weeks, the dose of sympathomimetics should be reduced.
Impact on the ability to engage in hazardous activities. During therapy, you should not engage in hazardous activities that require rapid motor and mental reactions (including driving a car).
Registration number
Trade name of the drug: Mezaton
International nonproprietary name:
phenylephrine
Dosage form:
injection
Compound:
1 ml of solution contains:
active substance phenylephrine hydrochloride -10 mg;
Excipients: glycerin, water for injection.
Description: transparent colorless liquid.
Pharmacotherapeutic group:
alpha adrenergic agonist
ATX code C01CA06
Pharmacological properties
Pharmacodynamics
Synthetic alpha 1-adrenergic stimulant, which has little effect on cardiac beta-blockers; is not a catecholamine (contains only one hydroxyl group in the aromatic ring). Causes constriction of arterioles and increased blood pressure(BP) with possible reflex bradycardia. Compared to norepinephrine and epinephrine, the increase in blood pressure is less dramatic, but lasts longer (it is less susceptible to the action of catechol-O-methyltransferase) and does not cause an increase in minute blood volume. The action begins immediately after administration and continues for 20 minutes (after intravenous administration), 50 minutes (with subcutaneous administration), 1-2 hours (after intramuscular injection).
Pharmacokinetics.
Metabolized in the liver and gastrointestinal tract (without the participation of catechol-O-methyltransferase). Excreted by the kidneys in the form of metabolites.
Indications for use
Collapse, arterial hypotension (associated with decreased vascular tone), in preparation for surgery and during operations, vasomotor and hay rhinitis, intoxication, as a vasoconstrictor during local anesthesia
Contraindications
Hypersensitivity to the drug, hypertrophic obstructive cardiomyopathy (including asymmetric septal hypertrophy), pheochromocytoma, tachyarrhythmia, atrial and/or ventricular fibrillation, metabolic acidosis, hypercapnia, hypoxia, arterial hypertension, hypertension in the pulmonary circulation, hypovolemia, severe stenosis aortic mouth, acute heart attack myocardium, porphyria. congenital deficiency of glucose-6-phosphate dehydrogenase, tendency to vascular spasms, pregnancy, lactation, age under 18 years (efficacy and safety have not been established).
Carefully: Prinzmetal's angina, history of occlusive vascular diseases, including arterial thromboembolism, atherosclerosis, thromboangiitis obliterans (Buerger's disease), frostbite, diabetic endarteritis, Raynaud's disease, thyrotoxicosis, elderly age, diabetes, at general anesthesia(fluorotane), renal dysfunction.
Directions for use and doses
Mezaton is administered intravenously, subcutaneously, intramuscularly, intranasally. In case of collapse, the drug is administered, as a rule, intravenously in doses of 0.1-0.3-0.5 ml of a 1% solution, diluted with 20 ml of 5% - 20% dextrose (glucose) solutions or 0.9% sodium chloride solution. The administration is carried out slowly, the administration is repeated if necessary. With the drip method, 1 ml of a 1% solution of Mezaton is administered in 250-500 ml of a 5% solution of dextrose (glucose). Adults are administered subcutaneously and intramuscularly in doses of 0.3-1 ml of a 1% solution.
In order to narrow the vessels of the mucous membranes of the nasal cavity and reduce the severity of inflammation, 0.25-0.5% solutions are instilled or the mucous membranes are lubricated with these solutions. To local anesthetics (per 10 ml of anesthetic solution) add 0.3-0.5 ml of 1% Mezaton solution.
Higher doses for adults: intravenous - single 0.005 g, daily - 0.025 g; subcutaneously and intramuscularly - one-time 0.01 g, daily - 0.05 g.
Side effect
From the outside of cardio-vascular system:
increased blood pressure, palpitations, ventricular fibrillation, arrhythmia, bradycardia, cardialgia.
From the outside gastrointestinal tract: dyspeptic symptoms;
From the central side nervous system: dizziness, fear, insomnia, anxiety, weakness, headache, tremor, paresthesia, convulsions, cerebral hemorrhage;
Other: pallor of the facial skin, ischemia of the skin at the injection site, in isolated cases, necrosis and scab formation are possible when it enters the tissue or during subcutaneous injections, allergic reactions.
Overdose
Symptoms: ventricular extrasystole, short paroxysms of ventricular tachycardia, a feeling of heaviness in the head and limbs, a significant increase in blood pressure.
Treatment: intravenous administration alpha-blockers (phentolamine) and beta-blockers (for heart rhythm disorders).
Interaction with other drugs
Phenothiazines, alpha-blockers (phentolamine), Furosemide and other diuretics reduce the hypertensive effect.
Monoamine oxidase inhibitors, oxytocin, ergot alkaloids, tricyclic antidepressants, furazolidine, procarbazine, selegiline, adrenostimulants increase the pressor effect, and the latter also increase arrhythmogenicity.
Beta-blockers reduce cardiac stimulating activity, and with reserpine, arterial hypertension is possible (due to depletion of catecholamine reserves in adrenergic endings, sensitivity to adrenergic agonists increases).
special instructions
During the treatment period, ECG, blood pressure, minute blood volume, blood circulation in the extremities and at the injection site should be monitored.
Before starting or during therapy, correction of hypovolemia, hypoxia, acidosis, and hypercapnia is required.
A sharp increase in blood pressure, severe bradycardia or tachycardia, persistent cardiac arrhythmias require discontinuation of treatment. To prevent a recurrent decrease in blood pressure after discontinuation of the drug, the dose should be reduced gradually, especially after long-term infusion. The infusion is resumed if systolic blood pressure decreases to 70-80 mmHg. Art.
During therapy, you should not engage in hazardous activities that require rapid motor and mental reactions (including driving a car).
Release form
Solution for injection 10 mg/ml.
1 ml in ampoules, enclosed in 10 pieces together with instructions for use and an ampoule scarifier in a cardboard pack.
Storage conditions
List B. In a place protected from light and out of reach of children, at a temperature not exceeding 25°C.
Best before date
3 years.
Do not use the drug after the expiration date indicated on the package!
Conditions for dispensing from pharmacies
On prescription.
Manufacturing company
LLC "Experimental plant "GNTsLS" Address: Ukraine, 61057, Kharkov, st. Vorobyova, 8
Alpha adrenergic agonist
Active substance
Phenylephrine hydrochloride (phenylephrine)
Release form, composition and packaging
1 ml - ampoules (10) - cardboard packs.
pharmachologic effect
Alpha1-adrenergic stimulant, which has little effect on beta-adrenergic receptors of the heart; is not a catecholamine (contains only one hydroxyl group in the aromatic ring). Causes constriction of arterioles and increased blood pressure (with possible reflex bradycardia). Compared with epinephrine, it increases blood pressure less sharply, but acts longer (less susceptible to the action of catechol-O-methyltransferase); does not cause an increase in minute blood volume.
The action begins immediately after administration and lasts for 5-20 minutes (after intravenous administration), 50 minutes (with subcutaneous administration), 1-2 hours (after intramuscular administration).
Pharmacokinetics
Metabolized in the liver and gastrointestinal tract (without the participation of catechol-O-methyltransferase). Excreted by the kidneys in the form of metabolites.
Indications
Parenterally:
- arterial hypotension;
- shock states (including traumatic, toxic);
- vascular insufficiency (including due to an overdose of vasodilators);
- as a vasoconstrictor during local anesthesia.
Intranasally:
- vasomotor and allergic rhinitis.
Contraindications
- hypersensitivity to the drug;
- hypertrophic obstructive cardiomyopathy;
- pheochromocytoma;
- ventricular fibrillation.
Carefully:
Metabolic acidosis, hypercapnia, hypoxia, angle-closure glaucoma, arterial hypertension, hypertension in the pulmonary circulation, hypovolemia, severe aortic stenosis, acute myocardial infarction, tachyarrhythmia, ventricular arrhythmia, occlusive vascular diseases (including a history) - arterial thromboembolism , atherosclerosis, thromboangiitis obliterans (Buerger's disease), Raynaud's disease, vascular tendency to spasms (including frostbite), diabetic endarteritis, thyrotoxicosis, diabetes mellitus, porphyria, glucose-6-phosphate dehydrogenase deficiency, combined use of monoamine oxidase inhibitors, with general anesthesia (fluorotane), impaired renal function, old age, age under 18 years (efficacy and safety have not been established).
Dosage
Intravenously slowly, in case of collapse - 0.1-0.3-0.5 ml of 1% solution, diluted in 20 ml of 5% dextrose solution or 0.9% solution. If necessary, the administration is repeated.
Intravenous drip - 1 ml of 1% solution in 250-500 ml of 5% dextrose solution.
Subcutaneously or intramuscularly, adults- 0.3-1 ml of 1% solution 2-3 times a day; children over 15 years old at arterial hypotension during spinal anesthesia- 0.5-1 mg/kg.
For constriction of blood vessels in the mucous membranes and reduction of inflammation lubricate or instill (solution concentrations - 0.125%, 0.25%, 0.5%, 1%).
At local anesthesia add 0.3-0.5 ml of 1% solution per 10 ml of anesthetic solution.
Higher doses for adults: subcutaneously and intramuscularly: single - 10 mg, daily - 50 mg; intravenously: single - 5 mg, daily - 25 mg.
Side effects
From the cardiovascular system: increased blood pressure, palpitations, ventricular fibrillation, arrhythmia, bradycardia, cardialgia.
From the side of the central nervous system: dizziness, fear, insomnia, anxiety, weakness, headache, tremor, paresthesia, convulsions, cerebral hemorrhage.
Other: pallor of the facial skin, ischemia of the skin at the injection site, in isolated cases, necrosis and scab formation are possible when it enters the tissue or during subcutaneous injections, allergic reactions.
Overdose
Symptoms: ventricular extrasystole, short paroxysms of ventricular tachycardia, a feeling of heaviness in the head and limbs, a significant increase in blood pressure.
Treatment: intravenous administration of alpha-blockers (phentolamine) and (for heart rhythm disturbances).
Drug interactions
Mezaton reduces the antihypertensive effect of diuretics and antihypertensive drugs medicines(methyldopa, mecamylamine, guanadrel, guanethidine).
Phenothiazines, alpha-blockers (phentolamine), and other diuretics reduce the hypertensive effect.
Monoamine oxidase inhibitors (furazolidone, procarbazine, selegiline), oxytocin, ergot alkaloids, tricyclic antidepressants, methylphenidate, adrenostimulants enhance the pressor effect and arrhythmogenicity of phenylephrine.
Beta-blockers reduce cardiac stimulating activity; in the presence of reserpine, arterial hypertension is possible (as a result of depletion of catecholamine reserves in adrenergic endings, sensitivity to adrenergic agonists increases). Inhalation drugs (chloroform, enflurane, halothane, isoflurane, methoxyflurane) increase the risk of severe atrial and ventricular arrhythmias, since they sharply increase the sensitivity of the myocardium to sympathomimetics.
Ergotamine, methylergometrine, oxytocin, doxapram increase the severity of the vasoconstrictor effect.
Reduces the antianginal effect of nitrates, which, in turn, can reduce the pressor effect of sympathomimetics and the risk of arterial hypotension (simultaneous use is possible depending on the achievement of the required therapeutic effect).
Thyroid hormones increase (mutually) the effect and the associated risk of coronary insufficiency (especially with coronary atherosclerosis).
special instructions
During the treatment period, ECG, blood pressure, minute blood volume, blood circulation in the extremities and at the injection site should be monitored.
In patients with arterial hypertension in case of drug-induced collapse, it is enough to maintain systolic blood pressure at a level lower than usual by 30-40 mm Hg.
Before or during therapy for shock conditions, correction of hypovolemia, hypoxia, acidosis and hypercapnia is mandatory.
A sharp increase in blood pressure, severe bradycardia or tachycardia, persistent cardiac arrhythmias require discontinuation of treatment.
To prevent a recurrent decrease in blood pressure after discontinuation of the drug, the dose should be reduced gradually, especially after long-term infusion.
The infusion is resumed if systolic blood pressure decreases to 70-80 mmHg.
It should be borne in mind that the use of vasoconstrictors during labor to correct arterial hypotension or as additives to local anesthetics against the background of drugs that stimulate labor (vasopressin, ergotamine, ergometrine, methylergometrine) may lead to a persistent increase in blood pressure in the postpartum period.
With age, the number of adrenergic receptors sensitive to phenylephrine decreases. Monoamine oxidase inhibitors, increasing the pressor effect of sympathomimetics, can cause headaches, arrhythmia, vomiting, hypertensive crisis, therefore, when patients take monoamine oxidase inhibitors in the previous 2-3 weeks, the dose of sympathomimetics should be reduced.
Impact on the ability to drive vehicles and operate machinery
During therapy, you should not engage in hazardous activities that require rapid motor and mental reactions (including driving a car).
Pregnancy and lactation
Adequate and strictly controlled studies on humans and animals on the effect of the drug on pregnant women have not been conducted; data on the release of the drug in breast milk are absent, based on which during pregnancy and during breastfeeding The use of the drug is possible with caution, only according to strict indications and under the supervision of a physician, assessing the benefit-risk ratio.
Storage conditions and periods
Store in a place protected from light and out of reach of children at a temperature not exceeding 25°C. Shelf life - 3 years.
The product is produced in the form of a 1% solution in one milliliter ampoules, it active substance is phenylephrine.
Synonyms for Mesaton
- Adrianol
- Visadrone
- Phenylephnine
Action
Mezaton is a vasoconstrictor that stimulates the a-adrenergic receptors of blood vessels and does not affect the b-receptor apparatus of the heart. The drug is able to cause spasm of arterioles and. Phenylephrine initiates pupil dilation and reduces intraocular pressure, but there is no effect on accommodation. The drug also has a mydriatic effect, although it does not manifest itself sharply.
Indications for use
Drug Mezaton prescribed to increase blood pressure in case of hypotension, collapse and hypotension, during preparation and during surgical interventions, in case of intoxication and infectious diseases, for the occurrence of vascular spasm in secretory renal anuria, vasomotor rhinitis, and for pupil dilation in iridocyclitis and iritis.
Application
In case of collapse, 1% solution of Mezaton should be injected into a vein in the amount of 0.3 and 0.5 milliliters in forty milliliters of 20 and 40% glucose solution. Up to one milliliter of 1% glucose solution is administered intravenously, for which five hundred milliliters of 5% glucose solution is prepared.
From 0.3 to one milliliter of 1% solution is injected intramuscularly and subcutaneously. To reduce inflammatory manifestations, the product is used by lubrication or instillation of 0.25-0.5% solution.
In order to dilate the pupil, two or three drops of 1-2% Mezaton solution are injected into the conjunctival sac.
Side effects
- weakness
- excessive agitation and irritability
- arrhythmia
- hypertension
- respiratory depression
- heart pain
- limb tremors
- oliguria
- ischemia
- paresthesia
- skin necrosis at the injection site
Contraindications
- for hypertension
- atherosclerosis
- acute pancreatitis
- hepatitis
- tendency to vasospasm
- under fifteen years of age
- during pregnancy and lactation
It should be taken into account that tricyclic antidepressants, MAO inhibitors, ergot alkaloids, and oxytocin increase the vasospastic effect of the drug. When used in parallel with reserpine, there is a risk of developing arterial hypertension.
Overdose
- heaviness in the head and limbs
- short episodes and ventricular extrasystoles
- increase in blood pressure
To stop the attack, a and b-adrenergic blockers are administered intravenously.
Additionally
Ampoules are stored in a place protected from the sun.
At chronic diseases myocardium, in elderly people with hyperthyroidism Mezaton is prescribed with caution.
When using Mezaton, you should monitor the ECG, the level of blood circulation at the injection site and extremities, and blood pressure.
During treatment, activities that require rapid mental and physical reactions should be abolished.
Similar drugs
- Ephedrine hydrochloride (Ephedrinihydrochloridum)
- Adrenaline hydrochloride (Adrenalinhydrochloridum)
- Adrenaline hydrotartrat (Adrenalinihydrotartras)
- Norepinephrine hydrotartras (Noradrenalinihydrotartras)
Analogs
These are medicines belonging to the same pharmaceutical group that contain different active substances(INN), differ from each other in name, but are used to treat the same diseases.
- - Solution for topical use
- - Substance-powder
- - Injection
- - Solution for injection 1 mg/ml
- - Solution
- - Pills
- - Concentrate for the preparation of solution for intravenous administration 2 mg/ml
Indications for use of the drug Mezaton
Mezaton is used to increase blood pressure during hypotension and collapse, during hypotension, during preparation and during surgical interventions, during infectious diseases, intoxications, for vasospasm during vasomotor rhinitis, secretory renal anuria, as well as for pupil dilation during iritis, iridocyclitis.
Release form of the drug Mezaton
solution for injection 10 mg/ml; 1 ml ampoule with ampoule knife, cardboard pack 10;
Pharmacodynamics of the drug Mezaton
As a vasoconstrictor, Mezaton stimulates the a-adrenergic receptors of blood vessels without affecting the b-receptor apparatus of the heart. Causes spasm of arterioles and increases blood pressure (possibly reflex bradycardia). The drug causes pupil dilation and lowers intraocular pressure, without affecting accommodation. It also has a mild mydriatic effect.
Pharmacokinetics of the drug Mezaton
Biotransformed in the liver and gastrointestinal tract (without the participation of catechol-O-methyltransferase). Excreted by the kidneys in the form of metabolites. The action begins immediately after administration and continues for 20 (after intravenous injection) - 50 minutes (with subcutaneous injection) - 1–2 hours (after intramuscular injection). At local application undergoes systemic absorption.
Use of the drug Mezaton during pregnancy
Use during pregnancy and lactation is only possible if the potential benefit to the mother exceeds possible risk for the fetus and child.
Contraindications to the use of the drug Mezaton
Atherosclerosis, hypertonic disease, tendency to vasospasm, age up to 15 years, acute pancreatitis and hepatitis.
Side effects of the drug Mezaton
Excitement, headache, irritability, weakness, hypertension, arrhythmia, respiratory depression, pain in the heart, oliguria, tremor of the limbs, paresthesia, ischemia and necrosis of the skin at the injection site.
Method of administration and dosage of the drug Mezaton
In case of collapse, Mezaton is injected into a vein in a dosage of 0.3 and 0.5 ml (1% solution) in 40 ml of 20 and 40% glucose solution. Up to 1 ml of 1% glucose solution (500 ml of 5% glucose solution) is injected intravenously.
Into the muscle and under the skin: from 0.3 to 1 ml of 1% solution, orally - 0.01-0.025 g 2-3 times a day.
To reduce inflammatory manifestations, 0.25-0.5% solutions are used by lubricating or instilling.
To dilate the pupil: 1-2% Mezaton solution is injected into the conjunctival sac, 2-3 drops.
Overdose of Mezaton
It manifests itself as short episodes of ventricular tachycardia and ventricular extrasystoles, a feeling of heaviness in the head and limbs, and increased blood pressure. Relief of an attack: intravenous administration of a and b-adrenergic blockers.
Interactions of the drug Mezaton with other drugs
MAO inhibitors, tricyclic antidepressants, oxytocin and ergot alkaloids enhance the vasospastic effect. Furosemide, phenothiazines, phentolamine weaken the pressor effect on blood vessels. At joint use With reserpine, the development of arterial hypertension is possible.
Precautions when taking Mezaton
During the treatment period, ECG, blood pressure, and wedge pressure should be monitored. pulmonary artery, cardiac output, blood circulation in the extremities and at the injection site. In case of arterial hypertension, it is necessary to maintain SBP at a level of 30–40 mmHg. lower than usual. Before or during therapy for shock conditions, correction of hypovolemia, hypoxia, acidosis, and hypercapnia is mandatory. A sharp increase in blood pressure, severe bradycardia or tachycardia, persistent cardiac arrhythmias require discontinuation of treatment. To prevent a recurrent decrease in blood pressure after discontinuation of the drug, the dose should be reduced gradually, especially after long-term infusion. The infusion is resumed if SBP decreases to 70–80 mm Hg.
Potentially excluded during therapy dangerous species activities that require speed of motor and mental reactions.
When applied topically after absorption through the mucous membrane, phenylephrine can cause systemic effects. Therefore, the use of phenylephrine 10% should be avoided. eye drops in infants and elderly patients. The use of 2.5% or 10% phenylephrine solution with MAO inhibitors, as well as within 21 days after their withdrawal, should be done with caution, because the development of systemic adrenergic effects is possible.
